Progenity to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Progenity, Inc. (Nasdaq: PROG), a biotechnology firm known for its molecular testing products, announced that CEO Dr. Harry Stylli will participate in two virtual investor conferences. The events are a fireside chat at the BTIG Virtual MedTech Conference on February 17, 2021, at 2 p.m. ET, and another at the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 3 p.m. ET. Live webcasts will be available on Progenity's investor website, with archived replays to follow each event.

Progenity aims to enhance healthcare precision through innovative testing and therapies.

SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, is scheduled to participate in two upcoming virtual investor conferences:

• A fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at 2 p.m. ET / 11 a.m. PT on February 17, 2021; and
  
  
• A fireside chat at the Raymond James 42^nd Annual Institutional Investors Conference at 3 p.m. ET / 12 p.m. PT on March 3, 2021.
  

A live audio webcast of the fireside chats will be available in the Investors section of the company’s website at progenity.com/presentations, with an archived replay available following each event.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436

FAQ

What is Progenity's participation in the upcoming investor conferences?

Progenity's CEO, Dr. Harry Stylli, will participate in two virtual investor conferences, including the BTIG Virtual MedTech Conference on February 17, 2021, and the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021.

When will the fireside chat at the BTIG Virtual MedTech Conference take place?

The fireside chat at the BTIG Virtual MedTech Conference is scheduled for February 17, 2021, at 2 p.m. ET.

How can I listen to Progenity's investor conference webcasts?

You can listen to Progenity's investor conference webcasts by visiting the Investors section of their official website, where live audio and archived replays will be available.

What is the focus of Progenity's molecular testing products?

Progenity focuses on developing molecular testing products that provide actionable information to enhance medical decision-making during crucial life stages.

What is the significance of Progenity's multi-omics approach?

Progenity's multi-omics approach combines genomics, epigenomics, proteomics, and metabolomics to improve diagnostic accuracy and patient outcomes through personalized healthcare solutions.